Cargando…
Use of patient-reported outcomes (PRO) data to complement exposure–response analysis in early clinical cancer drug development
BACKGROUND: This proof-of-concept retrospective case study investigated whether patient-reported outcomes (PRO) instruments, designed to capture symptomatic adverse event data, could identity a known exposure–response (ER) relationship for safety characterized in an original FDA analysis of an appro...
Autores principales: | Xia, Huiming, Booth, Brian P., Wang, Yaning, Fan, Chunling, Bhatnagar, Vishal, Kluetz, Paul, Fourie Zirkelbach, Jeanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656371/ https://www.ncbi.nlm.nih.gov/pubmed/37975967 http://dx.doi.org/10.1186/s41687-023-00651-2 |
Ejemplares similares
-
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma
por: Murugappan, Meena N., et al.
Publicado: (2023) -
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement
por: Fernandes, Laura L., et al.
Publicado: (2021) -
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022) -
Efavirenz exposure, alone and in combination with known drugs of abuse, engenders addictive-like bio-behavioural changes in rats
por: Möller, Marisa, et al.
Publicado: (2018) -
Immunopathology of terminal complement activation and complement C5 blockade creating a pro‐survival and organ‐protective phenotype in trauma
por: Yang, Zhangsheng, et al.
Publicado: (2022)